Skip to main content

IP Update: Recent Patents, Patent Applications Awarded to CalTech, Marina, Arrowhead, and More

Premium

Title: Triggered RNAi

Patent Number: 8,497,364

Filed: Feb. 27, 2009

Lead Inventor: Niles Pierce, California Institute of Technology

The patent, its abstract states, relates to “methods and compositions for … triggered RNAi … [which] is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, methods of silencing or modulating the expression of a target gene are provided. The methods generally comprise providing an initiator to a cell comprising a detection target and a silencing target gene, wherein the detection target is different from the silencing target gene, wherein binding of the detection target to the initiator initiates formation of an inactivator double-stranded RNA. The inactivator dsRNA can silence or modulate the expression of the silencing target gene.”


Title: Nucleic Acid Compounds with Conformationally Restricted Monomers and Uses Thereof

Application Number: 20130190383

Filed: April 26, 2011

Lead Inventor: Narendra Vaish, Marina Biotech

The invention comprises “single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that regulate the function or expression of nucleic acid molecules expressed in a cell or a cell regulatory system dependent upon a nucleic acid,” the patent application’s abstract states. “The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers. Certain nucleic acid compounds may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers. The nucleic acid compounds are useful in various therapeutic modalities.”


Title: In Vivo Polynucleotide Delivery Conjugates Having Enzyme-sensitive Linkages

Application Number: 20130190484

Filed: March 15, 2013

Lead Inventor: David Rozema, Arrowhead Research

The invention relates to “compositions for delivery of RNA interference polynucleotides to cells in vivo,” according to the patent application’s abstract. “The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.”


Title: Method of Regulating Gene Expression

Application Number: 20130191935

Filed: Jan. 9, 2013

Lead Inventor: Bryan Cullen, Duke University

The invention relates to “gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method,” the patent application’s abstract states. The application specifically claims the use of a DNA construct that produces a mature microRNA that inhibits a target gene.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.